| CAS NO: | 2622-26-6 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
| Cas No. | 2622-26-6 |
| 别名 | 氰噻嗪,Propericiazine; RP 8909 |
| Canonical SMILES | N#CC(C=C1N2CCCN3CCC(O)CC3)=CC=C1SC4=C2C=CC=C4 |
| 分子式 | C21H23N3OS |
| 分子量 | 365.49 |
| 溶解度 | DMSO: 250 mg/mL (684.01 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Pericyazine (Propericiazine) is a first-generation antipsychotic drug that is used as an adjunct to the short-term management of severe anxiety states and psychosis[1]. Pericyazine (Propericiazine) is a selective D2-dopamine receptor antagonist[2][3]. [1]. Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Subst Abuse Rehabil. 2012 May 28;3:43-7. [2]. Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypicalneuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [3]. Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. |
m.cnreagent.com